Background: Hyperphenylalaninemia (HPA, increased blood phenylalanine levels) refers to a disorder spectrum, with phenylketonuria (PKU) being the most common, caused by PAH gene variants in an autosomal recessive inheritance form. Genetic differences significantly influence phenotypical outcomes in HPA patients. This study investigates the genotype-phenotype correlation of HPA patients, aiming to evaluate treatment consistency based on specific genotypes and demonstrate that genotyping can provide guidance for optimal treatment. Methods: Genomic DNA was obtained from 50 PKU, 2 tetrahydrobiopterin (BH4) deficiency, and 1 dihydropteridin reductase deficiency patients for next-generation sequencing of HPA-associated genes. Variants were analyzed using the Sophia DDM program, dbSNP, ClinVar, Ensembl information services, and ACMG 2015 criteria. Allelic phenotypical values consistent with enzyme functionality based on literature data were assessed using anamnesis information. Results: Carriers of two null variants (homozygous/compound heterozygous) were unresponsive to BH4 therapy, reflecting the existing literature. Notably, BH4 therapy was also inadequate for two PKU patients who were compound heterozygous carriers with one null variant (P3, P10), even with other variants assumed protein function (PAH [NM_000277.3] c.1289T>C, c.143T>C). However, PAH variants c.1169A>G (P21) and c.898G>T (P25) demonstrated positive BH4 responses when compounding a null variant, along with a c.782G>A homozygous patient benefiting from BH4. Two novel variants were observed in PTS and QDPR genes, respectively. Conclusion: This study implies that genetic testing is plausible in predicting pretreatment BH4 testing outcomes, aiding in decision-making before patient evaluation, and providing valuable guidance to metabolism specialists during HPA treatment. With more HPA genotypes analyzed and clinical data published, genotyping will hold a better deterministic position toward patient prognosis and therapeutic management.
8 March 2025 in Egyptian Journal of Medical Human Genetics
Background: This study presents an adult 7p21 deletion patient, including a literature review specific to 7p21 deletion, and concludes recommendations toward such patients. A 47-year-old male with moderate-to-severe learning disability and significant dysmorphic features was seen in our Medical Genetics clinic. Initially, a chromosome analysis was requested considering a pre-diagnosis of Down syndrome with adult age, and other chromosomal abnormalities. Results: In karyotype analysis, one chromosome 7 was observed to have a deletion on its short arm. Subsequently, single nucleotide polymorphism array (SNP Array) analysis was pursued to confirm the abnormality seen in the chromosome analysis and to elucidate its details. The results indicated a 16-megabase loss in the 7p21.3-p15.3 regions. Conclusions: Patients with deletions of the short arm of chromosome 7 may exhibit various phenotypic features, including case-specific anomalies. Common abnormalities often linked to the heterozygous loss of 7p21 include a wide nasal bridge and ear shape abnormalities. Our 47-year-old patient presented with macroglossia and dysmorphic traits, suggesting macroglossia as a potential clinical finding for follow-up in adults. Further research is needed to confirm if all such specific anomalies are due to 7p genetic material loss.